Zymeworks EBITDA 2016-2022 | ZYME

Zymeworks ebitda from 2016 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Zymeworks Annual EBITDA
(Millions of US $)
2021 $-206
2020 $-177
2019 $-144
2018 $-30
2017 $-6
2016 $-37
2015 $-19
Zymeworks Quarterly EBITDA
(Millions of US $)
2022-06-30 $-64
2022-03-31 $-67
2021-12-31 $-39
2021-09-30 $-58
2021-06-30 $-66
2021-03-31 $-42
2020-12-31 $-35
2020-09-30 $-69
2020-06-30 $-40
2020-03-31 $-33
2019-12-31 $-71
2019-09-30 $-32
2019-06-30 $-28
2019-03-31 $-13
2018-12-31 $9
2018-09-30 $-19
2018-06-30 $-1
2018-03-31 $-19
2017-12-31 $34
2017-09-30 $-16
2017-06-30 $-9
2017-03-31 $-16
2016-12-31 $-10
2016-09-30 $-11
2016-06-30 $-6
2016-03-31 $-10
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.614B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00